| Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Co.'s initial focus is on developing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. We show 11 historical shares outstanding datapoints in our coverage of AVTE's shares outstanding history.|
Understanding the changing numbers of AVTE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AVTE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AVTE by allowing them to research AVTE shares outstanding history
as well as any other stock in our coverage universe.